Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue

Arteriosclerosis, Thrombosis, and Vascular Biology - United States
doi 10.1161/atvbaha.110.220988
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Cost Effectiveness of Proprotein Convertase Subtilisin/ Kexin Type 9 (PCSK9) Inhibitors

Cardiovascular Disorders and Medicine
2019English

PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke

Circulation. Genomic and precision medicine
GeneticsCardiovascular MedicineCardiology
2018English

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2018English

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Deficiency Is Protective Against Venous Thrombosis in Mice

Scientific Reports
Multidisciplinary
2017English

Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors

Clinical Research in Cardiology Supplements
Nuclear MedicineRadiologyMolecular BiologyStructural BiologyImagingMedicine
2019English

Lipoprotein(a) and Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Alzheimer’s Disease: A Genetic and Proteomic Multi-Cohort Study

PLoS ONE
Multidisciplinary
2019English

PCSK6 (Proprotein Convertase Subtilisin/Kexin Type 6)

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2017English

Management of Patients Eligible for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Economic Impact and Reform Proposals

Global and Regional Health Technology Assessment
Health Policy
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy